A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The patient is being asked to join this clinical research study to find out if lapatinib, an
agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface
of cancer cells in combination with everolimus, an agent that targets a protein in the cancer
cell, called mammalian target of rapamycin (mTOR) is effective in metastatic triple negative
breast cancers that are no longer controlled by standard chemotherapy.